Amgen CEO Sharer gets 38% pay increase to $21M

In a year when many drug CEOs saw their pay packages decline or remain stagnant, Amgen chief Kevin Sharer (photo) got a 38 percent bump. Sharer's 2010 compensation came to $21.1 million, up from $15.3 million in 2009--a figure that far outclasses several pharma CEOs' pay packages, even at far larger companies.

Sharer won a roughly four percent increase in base salary to $1.7 million, and his cash bonus amounted to just over $3.6 million, about four percent less than in 2009, according to an SEC filing. But his stock and option awards shot up nearly 65 percent to almost $15 million. To put this in context, Amgen grew sales by almost three percent for 2010, to more than $15 billion, but profits were flat at about $4.6 billion. The company did manage to launch two promising new drugs: the osteoporosis remedy Prolia and its twin sister Xgeva, which is approved as an adjunct cancer therapy. 

Meanwhile, Bristol-Myers Squibb chief Lamberto Andreotti's (photo) compensation amounted to almost $11 million, while GlaxoSmithKline CEO Andrew Witty (photo) got $3.75 million, $1.5 million less than 2009 because the company missed profit targets. 

- see Amgen's SEC filing
- read the story in the Ventura County Star
- get more from Dow Jones

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The Trump Administration has opened the doors for Florida and other states to import prescription drugs from Canada—despite industry objections.